Homoserine dehydrogenase as a selective target molecule for antifungal action

  • Hideyo Yamaguchi
Conference paper
Part of the NATO ASI Series book series (volume 69)

Abstract

Remarkable progress has been made recently in antifungal chemotherapy with the advent of imidazole-or triazole-containing antifungal drugs. However, their clinical usefulness appears to be limited by insufficiency of the selective toxicity. This is probably ascribable to the fact that both fungal and human cells share the common target molecule for attack of azoles, cytochrome P-450, although the affinity of recently developed triazoles such as itraconazole and fluconazole with this enzyme from fungal cells is much higher than that from host cells (Vanden Bossche et al., 1989). It should be those enzymes which are of vital importance for fungal growth but absent in human cells that provides the potential target for higher selectivity of an antifungal action. In the last decade, our laboratory has been involved, in collaboration with several other research groups, in the search for and preclinical evaluation of new antifungal compounds with a favorable profile of activity and safety. In the course of rather empirical screening of antifungal antibiotics with microbial culture filtrates, we discovered a couple of novel ones considered to be promising candidates or leads for clinically useful drugs. Among them is an antibiotic with aspartate-related structure, (s)2-amino-4-oxo-5-hydroxypentanoic acid (RI-331) (Fig. 1).

Keywords

Cysteine Serine Proline Arginine Glutamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Van den Bossche H, Marichal P, Gorrens J, Coene M-C, Willernsens G, Bellens D, Roels I, Moereels H, Janssen PAJ (1989) Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 32(Suppl 1): 35–52.Google Scholar
  2. Yamaguchi H, Uchida K, Hiratani T, Nagate T, Watanabe N, Omura S (1988) RI-331, a new antifungal antibiotic. Ann. N.Y. Acad. Sci. 544: 188–190.PubMedCrossRefGoogle Scholar
  3. Yamaki H, Yamaguchi M, Nishimura T, Shinoda T, Yamaguchi H (1988) Unique mechanism of action of an antifungal antibiotic RI-331. Drugs Expl. Clin. Res. 14: 467–472.Google Scholar
  4. Yamaguchi M, Yamaki H, Shinoda T, Tago Y, Suzuki H, Nishimura T, Yamaguchi H (1990) The mode of antifungal action of (s) 2-amino-4-oxo-5-hydroxypentanoic acid, RI-331 J. Antibiotics 43: 411–416.Google Scholar
  5. Yamaki H, Yamaguchi M, Imamura H, Suzuki H, Nishimura T, Salto H, Yamaguchi H (1990) The mechanism of antifungal action of (s)2-amino-4-oxo-5-hydroxypentanoic acid, RI-331; The inhibition of homoserine dehydrogenase in Saccharomyces cerevisiae (1990) Biochem. Biophys. Res. Commun. 168: 837–843.CrossRefGoogle Scholar
  6. Yamaki H, Yamaguchi M, Tsuruo T, Yamaguchi H (1992) Mechanism of action of an antifungal antibiotic, RI-331 (s) 2-amino-4-oxo-5-hydroxypentanoic acid; Kinetics of inactivation of homoserine dehydrogenase from Saccharomyces cerevisiae. J. Antibiotics 45: 750–755.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Hideyo Yamaguchi
    • 1
  1. 1.Research Center for Medical MycologyTeikyo University School of MedicineTokyoJapan

Personalised recommendations